Effectiveness and Safety of the Intermittently Scanned Continuous Glucose Monitoring System FreeStyle Libre 2 in Patients with Type 2 Diabetes Treated with Basal Insulin or Oral Antidiabetic Drugs: An Observational, Retrospective Real-World Study
Open accessThe DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
Intermittently Scanned Continuous Glucose Monitoring (isCGM) devices are increasingly being used in patients with type 2 diabetes mellitus (T2DM) on insulin therapy for their benefits regarding disease management. Evidence of isCGM use in patients with T2DM on basal or non-insulin therapy is lacking. This study aimed at assessing the efficacy and safety of isCGM in this population. This was an observational, retrospective, real-world study enrolling patients with T2DM who were starting the use of isCGM. Data from medical records (i.e., demographics, clinical characteristics, laboratory assessments, and isCGM metrics) were collected over three time periods (baseline, 3 and 6 months). The endpoints were glycated haemoglobin (HbA1c) changes and changes in isCGM metrics as defined by the International Consensus from baseline to 3 months and 6 months. Overall, 132 patients were included (69.5% male; mean age 68.2 ± 11.0 years; mean disease duration 19.0 ± 9.4 years; 79.7% on basal insulin ±non-insulin therapy; mean baseline HbA1c 8.1% ± 1.3%). The estimated mean change in HbA1c was statistically significant at three (−0.4 ± 1.0%; p = 0.003) and six months (−0.6 ± 1.3%; p < 0.0001). In conclusion, isCGM proved to be effective and safe in improving glycaemic control in patients with T2DM on basal insulin or non-insulin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A smaller retrospective observational study from Italy by Conti et al. included 132 adults living with T2DM (of whom 21.3% were noninsulin users) and demonstrated significant reductions in HbA1c of 0.6 ± 1.3% (p < 0.0001).”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“The study endpoints were to evaluate changes in HbA1c levels and changes in CGM metrics as defined by the International Consensus on Time in Range [18] from baseline to a 3-and a 6-month follow-up.”
MethodHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
Yaron, M., Roitman, E., Aharon-Hananel, G., Landau, Z., Ganz, T., Yanuv, I., Rozenberg, A., Karp, M., Ish-Shalom, M., Singer, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-0166 · Cited by 211
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0255-6 · Cited by 188
Roussel, R., Riveline, J.-P., Vicaut, E., de Pouvourville, G., Detournay, B., Emery, C., Levrat-Guillen, F., & Guerci, B. (2021) · Diabetes Care · doi:10.2337/dc20-1690 · Cited by 173 · cited 2×
“However, the data are not homogenous, and the majority of the studies are on national databases [8–12].”
BackgroundMonro, J. A., & Shaw, M. J. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.1.237s · Cited by 166 · cited 1×
“Alternatively, they can modify the meal composition or reduce the amount of food [20].”
BackgroundWada, E., Onoue, T., Kobayashi, T., Handa, T., Hayase, A., Ito, M., Furukawa, M., Okuji, T., Okada, N., Iwama, S., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001115 · Cited by 157 · cited 2×
“However, evidence regarding the use of isCGM in patients under basal insulin or noninsulin therapy is more limited [8–17].”
BackgroundResultInfluentialWright, E. E., Kerr, M. S. D., Reyes, I. J., Nabutovsky, Y., & Miller, E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0069 · Cited by 115 · cited 3×
“However, evidence regarding the use of isCGM in patients under basal insulin or noninsulin therapy is more limited [8–17].”
BackgroundCarlson, A. L., Daniel, T. D., DeSantis, A., Jabbour, S., Karslioglu French, E., Kruger, D., Miller, E., Ozer, K., & Elliott, T. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002590 · Cited by 69
Guerci, B., Roussel, R., Levrat-Guillen, F., Detournay, B., Vicaut, E., De Pouvourville, G., Emery, C., & Riveline, J.-P. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0271 · Cited by 69 · cited 1×
“…trials and real-world studies, showed that isCGM use was mainly associated with glycated haemoglobin improvement [8–16], a reduction of acute diabetes-related events (ADEs; i.e., severe hypoglycemia and diabetic ketoacidosis) [10] and a reduction of the rate of hospitalization for ADEs [9,10,12].”
BackgroundChoe, H. J., Rhee, E.-J., Won, J. C., Park, K. S., Lee, W.-Y., & Cho, Y. M. (2022) · Diabetes Care · doi:10.2337/dc22-0764 · Cited by 59 · cited 1×
“It has been shown that isCGM, together with the Self-Evaluation Of Unhealthy foods by Looking at postprandial glucose (SEOUL) algorithm, was able to improve HbA1c values [15].”
MethodElliott, T., Beca, S., Beharry, R., Tsoukas, M. A., Zarruk, A., & Abitbol, A. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211021374 · Cited by 49 · cited 1×
“In the literature, data from other cohorts show greater reduc-J tions in glycated haemoglobin during isCGM use across a similar follow-up period [13,14].”
BackgroundFlash CGM associated with event reduction in nonintensive diabetes therapy
(2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88780 · Cited by 49 · cited 1×
“…trials and real-world studies, showed that isCGM use was mainly associated with glycated haemoglobin improvement [8–16], a reduction of acute diabetes-related events (ADEs; i.e., severe hypoglycemia and diabetic ketoacidosis) [10] and a reduction of the rate of hospitalization for ADEs [9,10,12].”
BackgroundLu, J., Ying, Z., Wang, P., Fu, M., Han, C., & Zhang, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15328 · Cited by 39 · cited 1×
“The efficacy of both isCGM and rt-CGM in type 1 diabetes mellitus has been confirmed by a large body of evidence [1,3].”
BackgroundInsulin therapy in type 2 diabetes: what is the evidence?
Van Avendonk, M. J. P., & Rutten, G. E. H. M. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00981.x · Cited by 38 · cited 1×
“Controlling blood glucose levels in patients affected by T2DM using basal insulin therapy and no rapid insulin can be challenging [19].”
BackgroundEeg-Olofsson, K., Svensson, A.-M., Franzén, S., Ahmed Ismail, H., Törnblom, M., & Levrat-Guillen, F. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211067418 · Cited by 29
Zhou, Y., Sardana, D., Kuroko, S., Haszard, J. J., de Block, M. I., Weng, J., Jefferies, C., & Wheeler, B. J. (2024) · Diabetic Medicine · doi:10.1111/dme.15280 · Cited by 25 · cited 2×
“Real-time Continuous Glucose Monitoring (rt-CGM) does not require manual scanning, and it provides predictive alarms for hypo-or hyper-glycaemia, thus resulting in being superior to isCGM in terms of glycaemic control and cost-effectiveness [2].”
BackgroundMethodPolonsky, W. H., Fortmann, A. L., Soriano, E. C., Guzman, S. J., & Funnell, M. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0419 · Cited by 20 · cited 1×
“There was a significant gain in % TIR and a parallel drop in % TAR, together with an overall increase in well-being, and an improvement in healthy eating [21].”
BackgroundGao, Y., Zhou, M., Xu, X., & Chen, W. Y. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108314 · Cited by 13 · cited 2×
“Intermittently Scanned Continuous Glucose Monitoring devices provide continuous and real-time glucose monitoring, allowing individuals to track their glucose levels throughout the day and night without the need for finger pricking [1].”
BackgroundChen, M.-Y., Li, H., Shen, Y., Liu, B., Yan, R., Sun, X., Ye, L., Lee, K., Ma, J., & Su, X. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0994-9850 · Cited by 9 · cited 1×
“…randomized controlled clinical trials and real-world studies, showed that isCGM use was mainly associated with glycated haemoglobin improvement [8–16], a reduction of acute diabetes-related events (ADEs; i.e., severe hypoglycemia and diabetic ketoacidosis) [10] and a reduction of the rate of…”
BackgroundInvestigating Diabetes Mellitus Patients’ Experiences with Self Monitoring Blood Glucose Methods
Dragamestianou, A., Kontoteza, I. V., Siskou, O. C., Galanis, P., Papazafiropoulou, A. K., Konstantakopoulou, O., Gallos, P., Karagkouni, I., & Καϊτελίδου, Δ. (2022) · Studies in health technology and informatics · doi:10.3233/shti220768 · Cited by 6 · cited 2×
“According to a systematic review and meta-analysis of isCGM use in type 1 and type 2 diabetes, the use of these devices results in a 0.4% reduction in HbA1c for each 1% increase in baseline levels over 7.2% [22].”
BackgroundMethodInfluential
Cited by
Aronson, R., Abitbol, A., Bajaj, H. S., Cheng, A. Y. Y., Christopoulos, S., Harris, S. B., Jain, A. B., & Goldenberg, R. M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70008 · Cited by 33
Mittal, R., Koutras, N., Maya, J., Lemos, J. R. N., & Hirani, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1352302 · Cited by 19
Prato, S. D., Giorgino, F., Szafranski, K., & Poon, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15703 · Cited by 19
Miller, E., Chuang, J. S., Roberts, G. J., Nabutovsky, Y., Virdi, N., & Wright, E. E. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01619-1 · Cited by 9
“A growing body of evidence suggests that there are also benefits for individuals with T2D treated with less-intensive insulin and non-insulin therapies [25–31].”
BackgroundRatzki‐Leewing, A. A., Harris, S. B., RABASA-LHORET, R. P. R., & Poon, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16266 · Cited by 10
“14,19,34,35 This study provides estimates for the effectiveness of FSL in a Canadian population, including patient groups for whom FSL is not currently covered in other Canadian provinces and territories.”
Influential
Metadata
- Authors
- Conti, M., Massari, G., Meneghini, E., Pasquino, B., Agosti, B., Chinotti, F., Pintaudi, B., Girelli, A., & Bertuzzi, F.
- Affiliations
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Milan (IT)
- Corresponding author
- Bertuzzi, Federico
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2024-01-23
- Volume
- 13
- Issue
- 3
- Pages
- 642
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC10856078
- OpenAlex
- W4391135790
- Cited by
- 21
- References
- 24
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 5
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- intermittently scanned continuous glucose monitoring, FreeStyle Libre 2, type 2 diabetes, basal insulin, oral antidiabetic drugs, glycemic control, HbA1c, real-world effectiveness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.